ALMIRALL

Almirall reports H1 2026 EBITDA of €150.7 million (+23.7%) and net sales of €602.7 million (+7.5%), largely meeting or exceeding expectations. The growth was driven mainly by biologics: Ebglyss reached €84.5 million in sales (+88.2%) and Ilumetri €125.2 million (+10.5%), while the dermatology business in Europe grew by 18.1%. Management confirms the full-year guidance (net sales +9–12%, EBITDA €270–290 million); net income of €39.6 million was slightly below consensus and Ebglyss’s growth slowed in Q2, which dampened the share price recovery. » More on de.investing.com

Almirall reported Q1 net revenue of €291.0m (consensus €293.4m) and total revenues of €292.4m, slightly below expectations. Profitability was robust: EBITDA €67.5m (consensus €66.7m), EBIT €30.0m (consensus €29.3m), while net profit of €15.3m missed the consensus of €19.1m, weighed down by higher net financial expenses and a revaluation of an equity swap. The dermatology business grew 16.3% to €179.7m, driven by Ebglyss (€41.9m) and Ilumetri (€61.6m). Almirall confirmed its full-year outlook (net revenue €1,208–1,241m, EBITDA €270–290m) and reported a bispecific antibody candidate entering Phase I studies. » More on de.investing.com

Almirall reports net sales of €1,108.1m for fiscal 2025 (+12.4%) and an EBITDA of €232.9m, driven by strong sales of the biologics Ilumetri and Ebglyss in Europe. Ilumetri generated €234.4m, Ebglyss grew to €110.8m, while the US business suffered from competitive pressure and negative currency effects. For 2026 management expects revenue growth of 9–12% and an EBITDA of €270–290m; medium-term, Almirall aims for a double-digit CAGR through 2030 and an EBITDA margin around 25%. The balance sheet remains solid with a net leverage of 0.0x, but the stock fell about 1.56% after the announcement. » More on de.investing.com